Sirtuins in clinical trials of approaches to the treatment of neurodegenerative diseases

Progressive decline in physiological functions during aging leads to various diseases that place a heavy burden on patients, their families and society as a whole. Due to the increasing average life expectancy, the problems of prevention and treatment of age-related diseases are becoming more and more relevant. As part of the research on the regulation of the aging program, considerable attention has been focused on a small family of NAD+-dependent deacetylases and deacylases called sirtuins. These proteins are involved in the regulation of numerous intracellular processes, and disruption of their functions plays an important role in the development of various diseases, such as metabolic disorders, pathologies of the cardiovascular system and other organs, musculoskeletal diseases, and neurodegeneration. It is interesting to note that the activity of sirtuins can be modulated to some extent under the influence of pharmacological agents, which makes them promising targets for age-related diseases prevention and therapy. The presented review will describe the influence of sirtuins on the development and pathogenesis of neurodegenerative diseases, as well as discuss recorded clinical trials focused on its therapy with pharmacological agents potentially affecting the activity of sirtuin proteins.